Document:

EXHIBIT 10.1

  

  

  

  
    
      

      

    

    

    

    AMENDED AND RESTATED EMPLOYMENT AGREEMENT

    

    

    This Amended and Restated Employment Agreement (the "Agreement") is made on the 8th day of July 2021 (the “Effective Date”) between Iradimed Corporation, a
        Delaware corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida ("Iradimed" or the "Company"), and Chris Scott (the "Executive").

    WITNESSETH:

    WHEREAS, Executive currently serves as the Company’s Chief Financial Officer pursuant to an Employment Agreement (the “Employment Agreement”)
      dated December 16, 2013,

    WHEREAS, Iradimed desires to amend and restate the Employment Agreement (the “Amended and Restated Employment Agreement”) to include the
      responsibilities of Chief Operating Officer pursuant to the terms and conditions hereinafter stated, and;

    WHEREAS, Executive desires to serve as the Company’s Chief Operating Officer and Chief Financial Officer pursuant to the terms and
      conditions contained in this Agreement.

    
      NOW, THEREFORE, in consideration of the facts, mutual promises and covenants contained herein and intending to be legally bound thereby, Iradimed and Executive agree as follows:

      

      
        	
                1.

              	
                Employment. Iradimed shall employ Executive, and Executive hereby accepts employment by Iradimed, for
                    the period and upon the terms and conditions contained in this Amended and Restated Employment Agreement, beginning on the Effective Date.

              

      

      
        	
                2.

              	
                Title and Duties. Executive is to serve Iradimed as Chief
                    Operating Officer and Chief Financial Officer. Executive will report to the Chief Executive Officer and shall have such authority and responsibilities

                    as delegated or assigned from time to time by the Chief Executive Officer. Executive shall primarily be responsible for various business aspects
                    including Production, Supply Chain, Quality/Regulatory, Accounting & Finance, including Human Resources. Executive shall apply his previously
                    acquired knowledge of Iradimed and the medical device industry to assist in guiding the growth of the Company while meeting revenue and earnings goals, and all quality/regulatory requirements.

              

      

      
        	
                3.

              	
                Term. This Agreement shall commence as of the date hereof and shall continue until terminated in
                    accordance with Sections 7 and 8 below (the "Term").

              

      

      
        	
                4.

              	
                Policies. Except as provided herein, Executive shall be covered by and agrees to comply with all
                    Iradimed policies on the same terms as are applicable to other full- time Executives.

              

      

      
        	
                5.

              	
                Extent of Services. Executive shall devote substantially all of his entire business and professional time and attention to the faithful and diligent performance of Executive's duties hereunder, and will not engage in any other business, profession, or occupation for compensation or otherwise which would conflict or interfere with the performance of such services either
                    directly or indirectly without the prior written consent of Iradimed. Notwithstanding the foregoing, Executive will be permitted to (a) with the prior written consent of the Board (which consent
                    will not be unreasonably withheld or delayed), act or serve as a director, trustee, committee member, or principal of any type of business, civic, or charitable organization as long as such activities are disclosed in writing to
                    Iradimed's Board of Directors, and (b) purchase or own less than five percent (5%) of the publicly traded securities of any corporation; provided that, such ownership represents a passive investment 

              

      

    

  

  
    - 1 -

    
      

  

  
    
      
        	
                

                

              	
                and that the Executive is not a controlling person of, or a member of a group that controls, such corporation; provided
                    further that, the activities described in clauses (a) and (b) do not interfere with the performance of the Executive's duties and responsibilities to the Company as provided hereunder.

              

      

      
        	
                6.

              	
                Compensation.

              

      

      
        	
                (a)

              	
                Base Salary. The Company shall pay Executive a minimum annual salary of three hundred sixty thousand dollars ($360,000),
                    or in the event of any portion of a year, a pro rata daily amount of such annual salary. Executive's salary will be payable as earned in accordance with the Company's customary payroll practice and subject to tax withholdings as
                    applicable and required by law. Executive shall also be annually reviewed and eligible for merit increases as warranted by performance. Merit increases shall be
                    based on Executive's base salary and subsequent performance review(s), beginning December 31, 2021, and each year thereafter while Executive is employed by the Company.

              

      

      
        	
                (b)

              	
                Annual Bonus. Executive shall be eligible each fiscal year to receive cash bonus compensation based upon attaining
                    specific qualitative and/or quantitative goals as assigned by the CEO with consideration of any special situations in which the Executive may have demonstrated exemplary performance. The target value of such annual cash bonus awards
                    shall be detailed in the Company’s annual incentive plan however, the target value of such annual cash bonus shall be sixty percent (60%) of the Executive’s then prevailing Base Salary (the "Annual Bonus"). The Annual Bonus shall be
                    deemed to have been earned by, and payable to the Executive as of the date of the Board of Directors' determination of the amount of the Annual Bonus, regardless of whether Executive is still employed on the payment date.

              

      

      
        	
                (c)

              	
                Equity Compensation. The Company shall provide Executive with a restricted stock unit award that will be subject to the
                    terms and conditions of the Iradimed Restricted Stock Unit Agreement executed by Executive and Company (the "RSU Grant"). The RSU Grant will be awarded on the Effective Date, having a value of
                    $150,000, with the number of shares determined by the price of Iradimed Common Stock at the Nasdaq market closing price the trading day preceding the day of RSU Grant.

              

      

      The RSU Grant will vest over four years in annual installments, each equal to 25% of the RSU Grant, with the first installment vesting twelve (12) months from
        the Effective Date, and the second, third and fourth installments vesting respectively 24, 36 and 48 months from the Effective Date.

      
        	
                (d)

              	
                Annual Equity Bonus. Executive shall be eligible to receive annual equity awards pursuant to the Company’s annual incentive plan and consistent in
                  timing with the Company’s customary practices of granting such equity awards, including the equity award that is planned for December 2021. Annual equity awards, the nature of which shall be outlined in the Company’s annual incentive
                  plan, and have a targeted value of $400,000 which may be increased or decreased subject to Executive's performance against goals as set by the CEO and Board of Directors, as detailed in the Company’s annual incentive plan, with the number
                  of shares determined in a like manner to that indicated in 6(c) (the "Equity Bonus").

              

      

      
        	
                (e)

              	
                Benefits. Executive will be eligible to participate in Iradimed employee benefit plans that apply to all employees generally,
                  including without limitation, health and dental insurance programs, 401(k) plan, and paid personal leave.

              

      

      
        	
                (f)

              	
                Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in the furtherance of or in connection with the performance of Executive's duties hereunder, in accordance with the Company's expense 

              

      

    

  

  
    - 2 -

    
      

  

  

    
      	
              

              

            	reimbursement policy as in effect from time to time.

    

    
      	
              7.

            	
              Termination By Company.

            

    

    
      	
              (a)

              

            	
              Termination For Cause. Iradimed may terminate Executive's
                  employment hereunder for "Cause" upon: (a) any willful breach of any material obligation under this Agreement; (b) any gross negligence or willful
                  misconduct by Executive in the performance of his duties as an Iradimed employee; (c) Executive's conviction of or plea of guilty or nolo contendre to a crime that constitutes a felony under the laws of the United States or any state
                  thereof, if such felony or other crime is work-related, materially impairs the Executive's ability to perform services for the Company or results in material or financial harm to the Company
                  or its affiliates; (d) Executive's commission or participation in any act of fraud, embezzlement or dishonesty; (e) Executive's willful, material breach of an Iradimed policy. Executive shall not be terminated under subparagraph (a)
                  herein, unless he has received written notice of such breach from the Company's Chief Executive Officer, has had an opportunity to respond to the notice, and has failed substantially, where possible, to cure such breach within thirty (30)
                  calendar days of such notice. For purposes of this provision, no act or failure to act on the part of the Executive shall be considered "willful" unless

                  it is done, or omitted to be done, by the Executive in bad faith or without reasonable belief that the Executive's action or omission was in the best interests of the Company. Any act, or failure to act, based upon the authority given
                  pursuant to a resolution duly adopted by the Board or upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by the Executive in good faith and in the best interests of the Company.

            

    

    
      	
              (b)

            	
              Termination Without Cause. The Company may terminate this Agreement at any time by providing a Notice of Termination which includes a Date of Termination at least thirty (30) calendar days after delivery of the Notice of Termination. The
                  Company, at its option, may elect to have the Executive not report to work after the date of the written notice.

            

    

    
      	
              (c)

            	
              Notice of Termination. For purposes of this Agreement, “Notice of Termination” shall mean a notice, in writing, which shall indicate the specific
                termination provision of this Agreement relied upon as the basis for the Termination and the Date of Termination. The Date of Termination shall not be earlier than the date such Notice of Termination is delivered (as defined above);
                provided however, that the Company, at its option, may elect to have the Executive not report to work after the date of the written notice. “Date of Termination” means the date on which this Agreement shall terminate in accordance with the
                Notice of Termination and the provisions of this Agreement.

            

    

    
      	
              8.

            	
              Termination By Executive.

            

    

    
      	
              (a)

            	
              Termination for Good Reason. Executive may terminate his
                  employment hereunder by tendering his resignation to Iradimed. Unless otherwise consented to in writing by Executive, a resignation by Executive shall be for "Good Reason," where such resignation is tendered within sixty (60) days following: (a) a reduction in Executive's minimum Base Salary (other than a general reduction in Base Salary that affects all similarly situated executives in substantially the same proportions); (b) a
                  reduction in the Executive's Annual Bonus opportunity (other than a general reduction in Annual Bonus that affects all similarly situated executives in substantially the same proportions); (c) a material, adverse change in the Executive's title, authority, duties, or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by
                  applicable law); (c) the relocation of Executive's place of employment outside of a fifty (50) mile radius from the Company's current address; (d) any material breach by Iradimed of any material provision of this Agreement or any
                  material 

            

    

    
      
        
          - 3 -

          
            

        

        
          	

                	provision of any other agreement between the Executive and Iradimed;

                    (e) Iradimed's failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had
                    taken place, except where such assumption occurs by operation of law; (f) a material adverse change in the reporting structure applicable to the Executive. Prior to accepting Executive's resignation for any of the reasons set forth in this paragraph, the Company shall have an opportunity to rectify the matter that gave rise to Executive's resignation. If the matter is not
                    rectified within fifteen (15) days, Executive's resignation shall be deemed accepted by the Company.

        

        
          
            	
                    (b)

                  	
                    Resignation in connection with a Control Transaction. Executive may resign his position as a consequence of a Control Transaction (a "Change in Control Resignation") where such resignation is tendered within sixty (60) days following
                        any of the events listed below and such event occurs within twelve (12) months following a Control Transaction as defined in Section 8(c):

                  

          

          
            	
                    (i)

                  	
                    an assignment to Executive of any duties inconsistent with, or a significant change in the nature or scope of Executive's authority, responsibilities, title, reporting structure, or
                      duties from, those held by Executive immediately prior to the Control Transaction;

                  

          

          
            	
                    (ii)

                  	
                    a material reduction in Executive's annual salary or bonus program in effect immediately prior to the Control Transaction;

                  

          

          
            	
                    (iii)

                  	
                    the relocation of Executive's place of employment outside of a fifty (50) mile radius from the Company's current address;

                  

          

          
            	
                    (iv)

                  	
                    the failure to provide Executive with a number of paid personal leave days at least equal to the
                        number of paid personal leave days to which he was entitled in the last full calendar year prior to the Control Transaction;

                  

          

          
            	
                    (v)

                  	
                    the failure to provide Executive with substantially the same fringe benefits that were provided to Executive immediately prior to the Control Transaction, or with a package of fringe
                      benefits that, though one or more of such benefits may vary from those in effect immediately prior to the Control Transaction, is, in Executive's opinion, substantially at least as beneficial to Executive in all material respects to
                      such fringe benefits taken as a whole;

                  

          

          
            	
                    (vi)

                  	
                    the failure to obtain the express written assumption of, and agreement to, perform the
                        obligations in this Agreement by any successor.

                  

          

          
            	
                    (c)

                  	
                    Control Transaction. In this Agreement, a "Control Transaction" means a change in control of the Company defined as a transfer of ownership of more than
                        50% of the outstanding shares of the Company's stock in a single transaction or in a series of transactions that are related to the same or related parties. The regular daily trading of the Company's Common Stock, when aggregated over time, does not constitute a Control Transaction.

                  

          

          
            	
                    (d)

                  	
                    Termination Without Cause. The Executive may terminate this Agreement by delivering a Notice of Termination to the Company. The Date of Termination shall be
                      specified in the Notice of Termination; provided however, that the Date of Termination shall not be earlier than thirty (30) calendar days after delivery of the Notice of Termination.

                  

          

        

      

    

    
      - 4 -

      
        

    

     

    
      
        	
                9.

              	
                Death or Disability.

              

      

      
        	
                (a)

              	
                If, during the term of this Agreement, Executive becomes disabled such that he is not able to effectively discharge his duties under this Agreement due to physical or mental incapacity, to perform the essential functions of his job, with or without reasonable
                    accommodation, for a period of one hundred eighty days (180) out of any three hundred sixty-five (365) day period (a "Disability"), Iradimed's obligations under this Agreement shall cease, except that Executive may participate in any Iradimed-provided group disability benefits in accordance with the terms of those plans. However, in the event
                    that the Company temporarily replaces the Executive, or transfers the Executive' s duties or responsibilities to another individual on account of the Executive's inability to perform such duties
                    due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company. Any question as to the existence of the Executive's Disability as to which the Executive and the Company
                    cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the
                    Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement.

              

      

      
        	
                (b)

              	
                If the Executive's employment is terminated during the Term on account of the Executive's death or Disability, the Executive or the Executive's estate or beneficiaries, as the case may be,
                  shall be entitled to receive the following:

              

      

      
        	
                (i)

              	
                All accrued Base Salary and vacation time;

              

      

      
        	
                (ii)

              	
                A lump sum payment of all (A) unpaid Annual Bonuses and (B) the pro- rata Annual Bonus that the Executive would have earned for the fiscal year in which the death or Disability occurs, based on the achievement of applicable performance goals for such year, which shall be payable on the date that annual bonuses are paid to the Company's
                    similarly situated executives, but in no event later than two-and-a-half (2 1/2 ) months
                    following the end of the fiscal year in which the termination occurs.

              

      

      
        	
                (iii)

              	
                All vested equity grants.

              

      

      
        	
                10.

              	
                Consequences of Termination Other than From Death or Disability.

              

      

      
        	
                (a)

              	
                Compensation.

              

      

    

    	
            (i)

          	
            
              In the event that Iradimed terminates Executive's employment hereunder Without Cause or Executive resigns from Iradimed with Good Reason, then Iradimed shall pay to Executive (i) the full amount of any
                  earned but unpaid Base Salary through the date of termination; (ii) his accrued and unused vacation leave as of the last day worked, (iii) his approved business expenses; (iv) the full amount of any unpaid cash bonus awarded for any
                  fiscal years prior to the date of termination; (v) an amount equal to twelve (12) months Base Salary; (vi) subject to Executive's timely election to continue his existing health benefits under COBRA, and consistent with the terms of COBRA and the Company's health insurance plan, the Company will provide Executive a taxable lump sum
                  payment in an amount equal to pay the employer portion of the insurance premiums to continue Executive’s existing health benefits under COBRA for twelve (12) months following the termination date, as such premiums would be measured on the termination date, less applicable federal and state payroll deductions (the "COBRA Payment"); and (vii) all unvested equity awards pursuant to Sections

            

          

    
      - 5 -

      
        

    

    

    

    
      	
              

              

            	
              
                
                  6(c) and (d) above shall be immediately accelerated and deemed vested as of the termination date. Such payment shall be made as a lump sum within fifteen (15) days of the effective date of such termination.

                

              

            

    

    
      
        	
                (ii)

              	
                In the event that Company terminates Executive's employment as a result of a Control Transaction or Executive tenders a Change in Control Resignation, then Iradimed shall pay to
                    Executive (i) the full amount of any earned but unpaid Base Salary through the date of termination; (ii) his accrued and unused vacation leave as of the last day worked; (iii) his approved business expenses; (iv) the full amount of any unpaid cash bonus awarded for any fiscal years prior to the date of termination; (v) an amount equal to eighteen (18) months Base Salary; (vi) subject
                    to Executive's timely election to continue his existing health benefits under COBRA, and consistent with the terms of COBRA and the Company' s health insurance
                    plan, the Company will provide Executive a taxable lump sum payment in an amount equal to pay the employer portion of the insurance premiums to continue Executive’s existing health benefits under COBRA for eighteen (18) months following
                    the termination date, as such premiums would be measured on the termination date, less applicable federal and state payroll deductions (the "COBRA Payment"); and (vii) all unvested equity awards pursuant to Sections 6(c) and (d) above shall be immediately accelerated and deemed vested. Such payment shall be
                    made as a lump sum within fifteen (15) days of the effective date of such termination.

              

      

      
        	
                (iii)

              	
                In the event that Iradimed terminates Executive's employment hereunder for Cause or Executive resigns without Good Reason, Iradimed shall pay Executive his earned and unpaid Base Salary and
                  his accrued and unused vacation leave as of the last day worked, and approved business expenses and Iradimed shall have no obligation to make any further payments to or to provide any further benefits hereunder to Executive. Such payment
                  shall be made within fifteen (15) days of the effective date of resignation or termination.

              

      

      
        	
                11.

              	
                Ownership of Developments. All information, data, ideas, customer lists or other material which Executive develops or conceives during his employment,
                  (1) which are along the lines of business, work or investigations of the Company, or (2) which result from or are suggested by any work performed by Executive on behalf of the Company, shall be the exclusive property of the Company, shall
                  be promptly disclosed to the Company, and Executive will promptly execute and deliver all documents and do all other things necessary and proper to make all such information, data, ideas, customer lists or other material the absolute
                  property of the Company. Executive agrees to assist the Company in every proper way to obtain for the Company's benefit copyrights, patents, or other appropriate legal protection for information, data, ideas, customer lists or other
                  material that become the exclusive property of the Company.

              

      

      
        	
                12.

              	
                Notices. Any notice required or desired to be given under this Agreement shall be deemed given if in writing and sent by certified mail to the
                  addresses set forth below, or to the personal home address of Executive as maintained in the Company’s human resources systems. Notice shall be deemed given immediately if delivered in person or within three (3) days after mailing by
                  certified mail to the following addresses:

              

      

      	
              Chris Scott

              Iradimed Corporation

              1025 Willa Springs Dr.

              Winter Springs, FL 32708

            	
              Roger Susi

              Iradimed Corporation

              1025 Willa Springs Dr.

              Winter Springs, FL 32708

            

    

    

    

    
      - 6 -

      
        

    

    
    
      Any party may alter the address to which communications or copies are to be sent by giving notice of such change of address in conformity with the provisions
        of this paragraph for the giving of notice.

      
        	
                13.

              	
                Assignment. Executive acknowledges that his services are unique and personal and that he therefore may not assign his rights or delegate his duties
                  under this Agreement. This Agreement shall inure to the benefit of and be binding on Iradimed, its successors and assigns, including, without limitation, any entity which is or may become affiliated with or related to Iradimed.

              

      

      
        	
                14.

              	
                Waiver. Failure to insist upon strict compliance with any term
                    or condition of this Agreement shall not be deemed a waiver of such term or condition. The waiver of a breach of any term or condition of this Agreement by any party shall not be deemed to constitute the waiver of any other breach of
                    the same or any other term of condition.

              

      

      
        	
                15.

              	
                Entire Agreement. This Agreement contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made
                  no agreements, representations, or warranties relating to the subject matter of this Agreement that are not set forth herein. No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto.
                  Section headings are for convenience only and are neither a part of this Agreement nor a limitation of the scope of the particular sections to which they refer.

              

      

      
        	
                16.

              	
                Governing Law. This Agreement shall be construed in accordance with the laws of the State of Florida.

              

      

      
        	
                17.

              	
                Severability. The provisions of this Agreement are severable, and if any provision(s) or any part of any provision(s) is
                    held to be illegal, void or invalid under applicable law, such provision(s) may be changed to the extent reasonably necessary to make the provision(s), as so
                    changed, legal, valid and binding, and to reflect the original intentions of the parties as nearly as possible in accordance with applicable law. This Agreement shall be construed according to its fair meaning and not strictly for or
                    against either party.

              

      

      
        	
                18.

              	
                Venue and Jurisdiction. The parties to this Agreement hereby expressly and irrevocably elect as the sole judicial forum for the adjudication of any
                  matters arising under or in connection with this Agreement, and consent and subject themselves to the jurisdiction of the courts of the State of Florida and/or the United States District Court for the Middle District of Florida, Orlando
                  Division.

              

      

      
        	
                19.

              	
                Execution in Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original as against any party whose signature appears thereon, and all of which shall together constitute one and the same instrument. This Agreement shall
                    become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as
                    signatories.

              

      

      
        	
                20.

              	
                Named Party Litigation. In the event that Executive is a named Party with the Company involving Executive's former employer, Executive shall be
                  represented by the Company's defense attorneys as Executive. No cost for such defense shall be borne by Executive.

              

      

      
        
          
            
              	
                      21.

                    	
                      Section 409A.

                    

            

            

            
              	
                      (a)

                    	
                      
                        General Compliance. This Agreement is intended to comply with Section
                            409A of the Internal Revenue Code or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Notwithstanding any other provision of this Agreement, payments provided under this Agreement
                            may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this
                            Agreement that may be excluded from Section 409A either as

                      

                    

              
                

                  

                  
                    - 7 -

                    
                      

                  

                  
                    	
                            

                            

                          	
                            separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of
                              Section 409A, each installment payment provided under this Agreement shall be treated as a separate payment. Any payments to be made under this Agreement upon a termination of employment shall only be made upon a "separation
                              from service" under Section 409A.

                          

                  

                  
                    	
                            (b)

                          	
                            Specified Employees. Notwithstanding any other provision of this Agreement, if any payment or benefit provided to the Executive in connection with his termination of employment is determined to constitute "nonqualified deferred compensation" within the meaning of Section 409A and the Executive is determined to be a "specified employee" as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be paid until the first payroll date to occur following the six-month anniversary of the
                                Termination Date or, if earlier, on the Executive's death (the "Specified Employee Payment Date"). The aggregate of any payments that would
                                otherwise have been paid before the Specified Employee Payment Date and interest on such amounts calculated based on the applicable federal rate published by the Internal Revenue Service for the month in which the Executive's separation from service occurs shall be paid to the Executive in a lump sum on the Specified Employee Payment Date and thereafter, any remaining
                                payments shall be paid without delay in accordance with their original schedule.

                          

                  

                  
                    	
                            (c)

                          	
                            Reimbursements. To the extent required by Section 409A, each reimbursement or in-kind
                                benefit provided under this Agreement shall be provided in accordance with the following:

                          

                  

                  
                    	
                            (i)

                          	
                            the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for
                              reimbursement, or in-kind benefits to be provided, in any other calendar year;

                          

                  

                  
                    	
                            (ii)

                          	
                            any reimbursement of an eligible expense shall be paid to the Executive on or before the last day of the calendar year following the calendar year in which the expense was
                              incurred; and

                          

                  

                  
                    	
                            (iii)

                          	
                            any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.

                          

                  

                  
                    	
                            22.

                          	
                            Indemnification. In the event that the Executive is made a party or threatened to be made a party to any action, suit, or proceeding,
                              whether civil, criminal, administrative, or investigative (a "Proceeding"), by reason of the fact that the Executive is or was a director or officer of the Company, or any affiliate of the Company, or is or was serving at the
                              request of the Company as a director, officer, member, employee, or agent of another corporation or a partnership, joint venture, trust, or other enterprise, the Executive shall be indemnified and held harmless by the Company
                              to the maximum extent permitted under applicable law and the Company's bylaws from and against any liabilities, costs, claims, and expenses, including all costs and expenses incurred in defense of any Proceeding (including
                              attorneys' fees). Costs and expenses incurred by the Executive in defense of such Proceeding (including attorneys' fees) shall be paid by the Company in advance of the final disposition of such litigation upon receipt by the
                              Company of: (i) a written request for payment; (ii) appropriate documentation evidencing the incurrence, amount, and nature of the costs and expenses for which payment is being sought; and (iii) an undertaking adequate under
                              applicable law made by or on behalf of the Executive to repay the amounts so paid if it shall ultimately be determined that the Executive is not entitled to be indemnified by the Company under this Agreement.

                          

                  

                  
                    
                      	
                              (b)

                            	
                              
                                
                                  During the employment Term and for a period of three (3) years thereafter, the Company or any successor to the Company shall purchase and maintain,
                                    at its own

                                

                              

                            

                    

                  

                

              

            

          

        

      

      
        - 8 -

        
          

      

      
        	
                

                

              	
                
                  expense, directors' and officers' liability insurance providing coverage to the Executive on terms that are no less favorable than the coverage provided to other directors and similarly
                    situated executives of the Company.

                

              

        	

              

        

        

        [Signature Page Follows]

      

    

    

    

    
      - 9 -

      
        

    

     

    

    
      IN WITNESS WHEREOF, the
          parties have executed this Agreement as of the day and year first above written.

      

      

      
        	IRADIMED CORPORATION	
                 

              
	
                 

              	
                 

              
	
                 

              	
                 

              
	
                 

              	
                 

              
	
                 

              	
                 

              
	/s/ Roger Susi	
                 

              
	
                Roger Susi

                President and Chief Executive Officer

              	
                 

              
	
                 

              	
                 

              

        

        

      

      
        	Executive	
                 

              
	
                 

              	
                 

              
	
                 

              	
                 

              
	
                 

              	
                 

              
	
                 

              	
                 

              
	/s/ Chris Scott	
                 

              
	Chris Scott	
                 

              
	 Executive

              	
                 

              
	
                 

              	
                 

              

      

      

    

    

  

  - 10 -EX-10.2

 Exhibit 10.2 

AMENDMENT TO STOCK AND ASSET PURCHASE AGREEMENT 

This Amendment (this “Amendment”), dated as of July 6, 2021, is made and entered into by and between Perrigo Company plc
(“Seller”) and Padagis LLC (“Purchaser”, and together with Seller, the “Parties”). Capitalized terms used and not otherwise defined herein have the meanings set forth in the Agreement (as defined
below). 
 WHEREAS, Seller and Purchaser are parties to that certain Stock and Asset Purchase Agreement, dated March 1, 2021 (the
“Agreement”); and 
 WHEREAS, the Parties desire to amend the Agreement and agree to certain other matters as set forth in
this Amendment. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and in the Agreement and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

A.    Amendments to the Agreement. The Agreement is hereby amended as follows: 

1.    Section 5.4(h). A new Section 5.4(h) is hereby added to the Agreement, to read in
its entirety as follows: 
 “The Parties acknowledge that for purposes of providing certain services under the
Transition Services Agreement and to facilitate the transition to the independent operation of the Business and the Retained Seller Business, Purchaser and certain of its Representatives, and Seller and certain of its Representatives may have access
to a shared enterprise resource planning system (the “Shared ERP System”) following the Closing. Without limiting the covenants and agreements set forth in Section 5.3 or the other covenants and agreements
set forth in this Section 5.4 (including, in each case, any exceptions thereto): (i) Purchaser agrees that it shall not, and shall cause its Representatives not to, use, interfere with or make any adjustments, changes
or edits to, the Shared ERP System or any information contained therein to the extent relating to the Seller Retained Business or any Excluded Assets or Retained Liabilities; and (ii) Seller agrees that it shall not, and shall cause its
Representatives not to, use, interfere with or make any adjustments, changes or edits to, the Shared ERP System or any information contained therein to the extent relating to the Business or any Purchased Assets or Assumed Liabilities; provided,
that nothing in the foregoing clauses (i) or (ii) shall prohibit Purchaser, Seller or their respective Representatives, as applicable, from using or making adjustments, changes or edits to the Shared ERP system or any information contained
therein in connection with the provision or receipt of services pursuant to and in accordance with the terms of the Transition Services Agreement.” 

 2.    Section 5.7(j). Section 5.7(j) of
the Agreement is hereby amended and restated, to read in its entirety as follows: 
 “Nonqualified Deferred Compensation Plans.
Effective as of the Closing, Purchaser shall establish a nonqualified deferred compensation plan (the “Purchaser Deferred Compensation Plan”) for the benefit of each Transferred Business Employee who, as of immediately prior to the
Closing, was eligible to participate in the Perrigo Nonqualified Deferred Compensation Plan (the “Seller Deferred Compensation Plan”). Effective as of the Closing, the Purchaser Deferred Compensation Plan shall assume the account
balances of the Transferred Business Employees in the Seller Deferred Compensation Plans (which shall be fully vested as of the Closing), provided that an amount equal to the aggregate fair market value of such account balances as of the Closing
Date shall be treated as Funded Debt (and subject to adjustment in accordance with Section 2.9). In addition, Seller shall be responsible for making required Seller contributions accrued under the Seller Deferred
Compensation Plan by the Transferred Business Employees from January 1, 2021 through the Closing, which amount shall be paid to Purchaser or its Affiliate at the time such Seller contributions would otherwise be made to such Transferred
Business Employees had they remained active participants in the Seller Deferred Compensation Plan, and following such payment, Seller and its Affiliates and the Seller Deferred Compensation Plans shall be relieved of all Liabilities related to the
participation of the Transferred Business Employees in the Seller Deferred Compensation Plans. Purchaser shall undertake reasonable efforts to notify Seller when the account balances, and the amount thereof, of the Transferred Business Employees
under the Purchaser Deferred Compensation Plan are paid to the Transferred Business Employees (or their beneficiaries), with such notice to be made as soon as practicable after the end of each calendar year in which any such payments are made. 

Between the Closing and the such time as Purchaser implements a platform for participants in the Purchaser Deferred Compensation Plan to view
their account balances and manage their investments, the Transferred Business Employees shall be provided access by Seller to the platform applicable to the Seller Deferred Compensation Plan for purposes of viewing their historical account balance
as of the close of business on July 2, 2021; provided that Purchaser and its Affiliates shall indemnify Seller and its Affiliates for any Liabilities incurred or suffered by Seller or any of its Affiliates in connection with the
provision of such post-Closing services described in this sentence.” 
 3.    Section 5.7(p). A new
Section 5.7(p) is hereby added to the Agreement, to read in its entirety as follows: 
 “Flexible Spending
Accounts. Seller and Purchaser shall take all actions necessary or appropriate so that, effective as of the Closing Date the account balances (whether positive or negative) (the “Transferred FSA Balances”) under the applicable
flexible spending plan of Seller or its Affiliates (collectively, the “Seller FSA Plan”) of the Transferred Business Employees will be transferred to one (1) or more comparable plans of Purchaser or its Affiliates
(collectively, the “Purchaser FSA Plan”) and Purchaser or its Affiliates shall continue to administer the Transferred FSA Balances in the Purchaser FSA Plan in accordance with its terms and applicable Laws, including IRS Revenue
Procedure 2002-32 and IRS Notice 2021-15.” 

  
 2 

 B.    Amendments to the Seller Disclosure Schedules. The Seller
Disclosure Schedules are hereby amended as follows: 
 1.    Section 2.4(s) of the Seller Disclosure Schedules is hereby
amended to reflect the changes to specified Regulatory Approvals as set forth on Schedule A-1 to this Amendment. 

2.    Item 1 of Section 5.7(f) of the Seller Disclosure Schedules is hereby amended and restated, to read in its
entirety as set forth on Schedule A-2 to this Amendment. 
 C.    Other Agreements. 

1.    The Parties agree that the version of the Internal Restructuring Plan set forth on Schedule B to this
Amendment, together with the assignments and assumptions contemplated by (x) that certain Assignment and Assumption Agreement, dated as of July 6, 2021 by and between Perrigo UK Finco Limited Partnership, Perrigo Company plc, and Perrigo
Israel Pharmaceuticals Ltd. and (y) that certain Assignment and Assumption Agreement, dated as of July 6, 2021, by and between Perrigo Company plc and Padagis US LLC, reflect all amendments and modifications to the Internal Restructuring
Plan as of immediately prior to the Closing, and that the Parties have consented to each such amendment or modification. For the avoidance of doubt, the consent in the foregoing sentence does not extend to any documents or agreements that implement
the Internal Restructuring Plan, other than the agreements specified in clauses (x) and (y) of the foregoing sentence (it being understood that this sentence shall not imply that any such consent was required). 

2.    The Parties agree that notwithstanding that the versions of such agreements or instruments executed and delivered at
the Closing may deviate from the applicable forms attached to the Agreement, the Transition Services Agreement, Assignment and Assumption Agreement and Bill of Sale, Purchaser Manufacturing and Supply Agreement, Seller

  
 3 

 
Manufacturing and Supply Agreement, ORx Distribution Agreement and IP Assignment Agreements (including, in each case, the exhibits, schedules and annexes thereto) executed and delivered at the
Closing are the final and definitive versions of such agreement or instruments. 
 3.    The Parties agree that not more
than seven (7) Business Days following the Closing Date, Purchaser will provide written notice to Seller specifying Purchaser’s final determination as to whether Purchaser will (a) instruct Seller to (subject to Section 2.10(h)
of the Agreement regarding the sharing of Specified Consent Fees) pay the fee contemplated by Section 10.6.2 of the Contract set forth on Item #3 of Section 2.10(h) of the Seller Disclosure Schedules (the “Specified Consent
Contract”) or (b) deliver written acceptance of the contractual obligation to comply with the restrictions set out in clauses 10.2.1 to 10.2.5 of the Specified Consent Contract in accordance with Section 10.6.1 of the Specified
Consent Contract (in which case Purchaser will deliver, within one (1) Business Day, such written acceptance). 

  
 4 

 4.    Seller covenants and agrees that any dividend or other
distribution in respect of shares of an Israeli Purchased Entity (or deemed dividend or distribution in respect of shares of an Israeli Purchased Entity) contemplated by the settlement agreement entered into with the Israel Tax Authority prior to
Closing (an “Israel Settlement Distribution”) will have been made prior to the Closing. For the avoidance of doubt, and without expanding or modifying the definition of Excluded Taxes, the Parties acknowledge and agree that any Tax
imposed on any Israeli Purchased Entity by the Israel Tax Authority on any Israel Settlement Distribution shall constitute an Excluded Tax for all purposes of the Agreement. 

5.    The Parties agree that Purchaser shall not be required to pay or cause to be paid to Seller the amount of any Tax
Benefit pursuant to the provisions of Section 6.10(a) of the Agreement to the extent that the Tax Items that resulted in such Tax Benefit were actually utilized to reduce the amount of Excluded Taxes (including by virtue of any such Tax Item
being treated as a deduction in a Pre-Closing Period) and actually reduced the amount of a payment made by Seller or any of its Subsidiaries (including the Purchased Entities prior to the Closing), whether
such payment was made to an applicable Tax Authority or as an indemnification payment required to be made by Seller pursuant to the Agreement, in respect of Excluded Taxes. For the avoidance of doubt, nothing in this paragraph shall be interpreted
as modifying Purchaser’s obligations under Section 6.10(a) of the Agreement in respect of a Tax Benefit resulting from a Tax Item that was utilized to reduce the amount of Excluded Taxes if Seller or any of its Subsidiaries (including the
Purchased Entities prior to the Closing) has previously paid (whether to the applicable Tax Authority or as an indemnification payment pursuant to the Agreement) the amount of such Excluded Taxes that was determined without taking into account the
effect of such Tax Item. 
 6.    The Parties agree that the matter set forth on Schedule C to this Amendment and
any claims, causes of action, defenses and rights of offset or counterclaim, or settlement agreements arising therefrom, is a Purchased Asset. 

7.    The Parties agree to work in good faith to negotiate and execute an ex-U.S.
distribution/supply agreement within 30 days of Closing in respect of the products set forth on Schedule D to this Amendment, with economic terms consistent with the economics as between the Retained Seller Business and the RX Business
in effect as of immediately prior to Closing and consistent with the 

  
 5 

 
carve-out financials provided by Seller to Purchaser for the Rx Business. The legal terms and risk allocation will be based upon the relative economic
benefits of the Parties. If the Parties agree on a cost plus arrangement, then the terms will be based upon the supply agreements with proportional limits of liability. 

8. The Parties agree to the matters set forth on Schedule E to this Amendment. 

D.    Miscellaneous. This Amendment and the Agreement, together, contain the complete agreement among the Parties
and supersede any prior understandings, agreements, letters of intent, or representations by or among such parties, written or oral, that may have related to the subject matter hereof in any way. Except as expressly set forth above, the Agreement,
as amended hereby, shall remain in full force and effect, and this Amendment does not amend or waive any other term or condition of the Agreement. The terms and provisions of Article X of the Agreement are incorporated herein by reference as if set
forth herein in their entirety and shall apply mutatis mutandis to this Amendment. 
 [Remainder of page intentionally left blank]

  
 6 

 IN WITNESS WHEREOF, the Parties have executed or caused this Amendment to be executed as of
the date first written above. 
  

			
	PERRIGO COMPANY PLC
		
	By:	 	 /s/ Murray S. Kessler

		 	 Name: Murray S. Kessler
 Title:
  President and Chief Executive Officer

 
			
	PADAGIS LLC
		
	By:	 	 /s/ George Aitken-Davies

		 	 Name: George Aitken-Davies
 Title:
  Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]